Free Trial

CRISPR Therapeutics (CRSP) Competitors

CRISPR Therapeutics logo
$58.94 -1.14 (-1.89%)
As of 01:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, ILMN, and GMAB

Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Illumina (ILMN), and Genmab A/S (GMAB). These companies are all part of the "med - biomed/gene" industry.

CRISPR Therapeutics vs. Its Competitors

Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Allogene Therapeutics has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500.

Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allogene TherapeuticsN/AN/A-$257.59M-$1.23-1.02
CRISPR Therapeutics$37.31M136.00-$366.25M-$4.52-13.00

Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Allogene Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Allogene TherapeuticsN/A -52.98% -41.28%
CRISPR Therapeutics -1,023.64%-20.08%-17.13%

In the previous week, CRISPR Therapeutics had 11 more articles in the media than Allogene Therapeutics. MarketBeat recorded 12 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.47 beat Allogene Therapeutics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CRISPR Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Allogene Therapeutics currently has a consensus price target of $8.44, indicating a potential upside of 572.86%. CRISPR Therapeutics has a consensus price target of $71.75, indicating a potential upside of 22.12%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.53

Summary

Allogene Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

Get CRISPR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRSP vs. The Competition

MetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.06B$2.96B$5.58B$9.01B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-12.9821.4727.5120.20
Price / Sales136.00259.84415.84172.51
Price / CashN/A41.8337.0657.97
Price / Book2.607.788.085.61
Net Income-$366.25M-$55.05M$3.17B$248.50M
7 Day Performance12.66%5.38%3.57%4.92%
1 Month Performance36.83%3.87%3.74%7.42%
1 Year Performance5.75%5.72%33.78%21.48%

CRISPR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRSP
CRISPR Therapeutics
2.4468 of 5 stars
$58.76
-2.2%
$71.75
+22.1%
+9.2%$5.06B$37.31M-12.98460Analyst Forecast
Options Volume
Gap Up
ALLO
Allogene Therapeutics
2.996 of 5 stars
$1.15
-2.5%
$8.44
+634.3%
-47.4%$251.54M$20K-0.93310
AXSM
Axsome Therapeutics
4.7359 of 5 stars
$104.08
+0.7%
$172.33
+65.6%
+38.3%$5.12B$385.69M-18.04380
BEAM
Beam Therapeutics
2.6711 of 5 stars
$17.14
+2.0%
$48.75
+184.4%
-10.0%$1.72B$63.52M-3.72510Gap Up
EDIT
Editas Medicine
4.0586 of 5 stars
$2.25
-1.3%
$4.70
+108.9%
-37.3%$188.35M$35.84M-0.74230
KALA
KALA BIO
3.6828 of 5 stars
$4.85
+5.0%
$13.50
+178.4%
-11.4%$31.29MN/A-0.5930News Coverage
Gap Up
MRNA
Moderna
4.4704 of 5 stars
$27.53
+1.4%
$46.61
+69.3%
-71.7%$10.65B$3.24B-3.155,800Gap Up
NTLA
Intellia Therapeutics
4.6354 of 5 stars
$9.44
-1.3%
$33.37
+253.5%
-45.5%$977.80M$57.88M-1.80600
VRTX
Vertex Pharmaceuticals
4.4624 of 5 stars
$444.51
+0.7%
$511.62
+15.1%
-1.4%$114.15B$11.02B-113.406,100Positive News
Analyst Revision
ILMN
Illumina
4.8982 of 5 stars
$95.17
+0.4%
$127.39
+33.9%
-8.7%$15.07B$4.37B-15.689,030Trending News
Analyst Forecast
GMAB
Genmab A/S
4.1764 of 5 stars
$20.56
+0.3%
$37.60
+82.9%
-15.8%$13.18B$3.12B11.682,682News Coverage
Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:CRSP) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners